Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC

I'll research this case to build an accurate overview. Let me start with searches on the case, parties, and patents.

Let me dig into the specific patents, the procedural history, and the linkage to the Supreme Court on-sale bar case.

I'll research this case across PACER-related sources, court opinions, and PTAB records.

I have the key starting point: the D. Del. case was a protective action parallel to a D.N.J. case. Let me dig into the substantive litigation, PTAB proceedings, and outcome.

Now let me research the PTAB proceedings and the related D.N.J. consolidated litigation where the substantive fight occurred.

Bottom line up front

The D. Del. case 1:15-cv-00865 was a short-lived, "protective" parallel filing, not the case that decided anything. Filed 2015-09-24, it was voluntarily dismissed without prejudice on 2015-12-01 and terminated 2015-12-02 — before any answer, counterclaim, motion, Markman, discovery, or trial. The FJC Integrated Database classifies its procedural progress as "No court action (before issue joined)" and its disposition as "Voluntarily dismissed." The real palonosetron fight between Helsinn (with Roche Palo Alto) and Fresenius Kabi ran in a consolidated D.N.J. action before Judge Mary L. Cooper, and the dispositive validity law came out of the Teva/Dr. Reddy's/Sandoz branch of that consolidated litigation, culminating in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), aff'd, 586 U.S. 123 (2019).

A caveat on sourcing: I was cut off by a research-step limit before I could fully verify the institution/outcome of the parallel PTAB proceedings, so the IPR/PGR discussion below is flagged as partially unverified.

---

1. Filing and initial pleadings (D. Del. 1:15-cv-00865)

Why the two-track filing? Helsinn's own complaint explains it: the 45-day window under 35 U.S.C. § 355(j)(5)(B)(iii) to sue on the Paragraph IV notice and perfect the statutory stay of FDA approval. The D. Del. complaint expressly described itself as "a further protective measure with regard to this statutory" right, filed because Helsinn had already sued Fresenius in New Jersey. In other words, 1:15-cv-00865 was a venue hedge to secure the stay, not a case intended to be litigated.

Answer / counterclaims: None. The case was dismissed before issue was joined, so there are no Rule 12 answers or declaratory-judgment counterclaims on this docket. (Fresenius's answer, affirmative defenses, and counterclaims were filed in the D.N.J. track instead — e.g., its Answer in No. 3:15-cv-07378, asserting invalidity/unenforceability/non-infringement. Plaintiff-side counsel of record in Delaware were Jack B. Blumenfeld, Karen Jacobs, and Maryellen Noreika of Morris, Nichols, Arsht & Tunnell.)

---

2. No pre-trial motions, Markman, discovery, or trial in this case

Because of the voluntary dismissal, this docket contains none of: motions to dismiss, transfer, or stay pending IPR; summary judgment; a Markman hearing; discovery milestones; trial; JMOL/new-trial/fee motions. Any such events occurred in the companion D.N.J. track (below) or in the earlier D. Del. palonosetron cases (e.g., C.A. No. 13-688-GMS, consolidated, which produced an Order Construing the Terms of U.S. Patent Nos. 7,947,724; 7,947,725; 7,960,424; 8,598,219 & 8,729,094 — construing, inter alia, "said formulation is stable at 24 [18] months when stored at room temperature" to its plain and ordinary meaning, and rejecting an implied pH limitation for the '219/'094 patents).

---

3. Where the substance actually happened: the D.N.J. consolidated litigation

Helsinn Healthcare S.A. v. Dr. Reddy's Labs. (and Teva/Sandoz), No. 11-3962 (MLC)(DEA), consolidated, D.N.J. (Cooper, J.)

• Bench trial: 11 days in June 2015 (June 2–5, 8–12, 15–16), with closing arguments 2015-08-12.
• 2015-04-22 (Dkt. 290): Memorandum opinion construing preamble language of the '219 patent claims.
• 2015-11-13: Memorandum opinion; 2015-11-16: Final Judgment — asserted claims of the '724, '725, and '424 patents valid and infringed; '219 claims 1, 2, 6 valid and infringed by Teva's 0.25 mg/5 mL product but not infringed by the 0.075 mg/1.5 mL product. FDA approval of Teva's ANDA No. 090713 set no earlier than 2024-07-30 (patent expiry plus pediatric exclusivity).
• 2016-03-03: Supplemental opinion, Helsinn Healthcare S.A. v. Dr. Reddy's Labs. Ltd., 387 F. Supp. 3d 439 (D.N.J. 2016), 2016 WL 832089 — rejecting Teva's on-sale bar and written-description attacks. Critically, the court held that the post-AIA § 102(a)(1) on-sale bar requires a public sale of the invention — so Helsinn's confidential-ish MGI agreements (publicly announced, but dosage undisclosed) did not invalidate the '219 patent.
• 2017-05-01: Federal Circuit reverses (Dyk, Mayer, Moore): Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017). The panel held the invention was "on sale" pre-critical date under contract-law principles (UCC § 2-105(2); FDA approval contingent status irrelevant), was ready for patenting (reduced to practice), and that "if the existence of the sale is public, the details of the invention need not be publicly disclosed" — so the AIA on-sale bar applied and the asserted claims were invalid.
• 2019-01-22: Supreme Court affirms, unanimously (Thomas, J.), 586 U.S. 123, 139 S. Ct. 628 — a commercial sale to a third party obligated to keep the invention confidential can place it "on sale" under § 102(a)(1); "secret sales" remain invalidating prior art.
• 2018-06-03 (approx.): Cert petition activity — Helsinn, 585 U.S. 1015 (2018) (cert granted 2018-06-25).

As to Fresenius Kabi itself: Fresenius's ANDA/505(b)(2) dispute was litigated within the consolidated D.N.J. track (Nos. 15-7015/15-7378), where it filed answers and counterclaims (asserting, in one of those pleadings, the '724, '981, '218, '980, and '905 patents). I found a third-party representation (a 2018 Sagent Pharmaceuticals brief) stating that Fresenius Kabi was among five ANDA sponsors that had "settled their cases with Helsinn" and held tentative approval for generic palonosetron. I could not independently confirm the exact Fresenius–Helsinn settlement date or terms, so treat that as unverified.

---

4. Parallel PTAB proceedings

PTAB activity on the palonosetron family clearly existed, and the patent file wrappers cross-reference it, but my sourcing here is incomplete:

• IPR2015-01550, IPR2015-01551, IPR2015-01553, IPR2015-01554 — cited together in the prosecution record (e.g., the Gandara 1998 reference appears as "Exhibit 1027 of IPR2015-01550, -01151, -01553, -01554").

I'll research the counsel of record for Helsinn Healthcare S.A. in this case.

Let me pull the actual docket and complaint to identify counsel of record.

Let me get the complaint's signature block and confirm the of-counsel/out-of-state attorneys.

Counsel of Record — Plaintiff Helsinn Healthcare S.A., Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00865-GMS (D. Del.)

Important framing notes first

• The plaintiff side in this docket had two plaintiffs: Helsinn Healthcare S.A. and Roche Palo Alto LLC (Roche was also a co-plaintiff and, on the original complaint, a co-owner of several Aloxi® palonosetron patents). See D.I. 1 (COMPLAINT, filed 9/24/2015) and D.I. 7 (AMENDED COMPLAINT, filed 10/14/2015). The case metadata lists only Helsinn; that is incomplete but not wrong — Helsinn is the first-listed plaintiff.
• The case resolved before issue joined. Helsinn and Roche filed a Notice of Voluntary Dismissal of all claims without prejudice on Dec. 1, 2015 (D.I. 8), and the case was terminated Dec. 2, 2015. The FJC IDB record confirms the disposition as "Voluntarily dismissed," procedural progress "No court action (before issue joined)." Consequence: no answer, no scheduling order, and no pro hac vice admissions appear on this docket. Any out-of-state "national counsel" therefore never formally entered an appearance here. Plaintiff-side activity (the complaint, the amended complaint, the Rule 7.1 disclosure, the dismissal) was handled by the Delaware firm of record.
• CourtListener's parties page for this docket shows only three plaintiff-side attorneys — all from the same firm. (CourtListener parties page); (Docket page).

---

Attorneys of record for Plaintiffs Helen Healthcare S.A. / Roche Palo Alto LLC (confirmed on the 15-865 docket)

Firm: Morris, Nichols, Arsht & Tunnell LLP — 1201 N. Market Street, P.O. Box 1347, Wilmington, DE 19899 (302-658-9200)

Confirmation of the plaintiff's Delaware firm of record comes from the docket entries themselves (Clerk's "Report to the Commissioner of Patents and Trademarks," the Rule 7.1 disclosures, and the amended complaint/dismissal efilings attributed to Jacobs) and from UniCourt's docket summary, which lists Blumenfeld, Karen Jacobs, and Maryellen Noreika as the plaintiff attorneys, all "Designation Retained." (UniCourt docket summary)

---

Out-of-state / "of counsel" members of the Helsinn trial team (NOT shown appearing in 15-865)

The complaint in 15-865 was a near-identical parallel of Helsinn's contemporaneous filings in the District of New Jersey (C.A. No. 15-7015 (MLC)(DEA), filed 9/23/2015 — which itself certified D. Del. 15-865 as a related case). In those parallel and related Helsinn Aloxi® filings, Helsinn's national counsel was Paul Hastings LLP (New York) and Roche's was Loeb & Loeb LLP (New York):

• Joseph M. O'Malley, Jr. — Paul Hastings LLP, 75 East 55th Street, New York, NY; Helsinn's lead national patent counsel on the Aloxi® campaign (also of counsel on the earlier Delaware Aloxi® complaints). Role: of counsel (national lead).
• Bruce M. Wexler; Eric W. Dittmann; David M. Conca; Gary Ji; Angela C. Ni — Paul Hastings LLP, New York. Role: of counsel (Helsinn).
• Mark E. Waddell — Loeb & Loeb LLP, 345 Park Avenue, New York, NY. Role: of counsel for co-plaintiff Roche Palo Alto LLC.

Caveat — this is an inference, not docket-confirmed for 15-865. The signature blocks I could retrieve showing these attorneys as "OF COUNSEL" are from (i) the related Delaware Aloxi® consolidated case C.A. No. 13-688-GMS (stipulation filed June 2014, listing Morris Nichols as counsel and Paul Hastings/Loeb & Loeb as of counsel) and (ii) the New Jersey 15-7015 / Reddy / Sandoz filings (Oct. 8, 2015 and earlier certification and complaint signature blocks). Because 15-865 was voluntarily dismissed before issue joined, I found no pro hac vice motion, no "of counsel" signature block, and no attorney-appearance entry for these Paul Hastings or Loeb & Loeb attorneys on the 15-865 docket itself. Treat them as Helsinn's known national counsel team on this patent family, but not as formally appearing in this docket.

Representative source showing the Paul Hastings/Loeb & Loeb of-counsel structure on the parallel Aloxi® filings: D.N.J. 15-7015 Amended Complaint signature/certification pages (docketalarm PDF).

---

Contradictions / gaps flagged

1. Case metadata says plaintiff = Helsinn only. The docket shows Roche Palo Alto LLC was a co-plaintiff in 15-865 (D.I. 1; D.I. 7). Flagging per your instruction.
2. "Terminated 2015-12-02" is correct and matches the FJC IDB and the D.I. 8 voluntary dismissal (filed 12/1/2015, case terminated 12/2/2015). (FJC IDB page)
3. Noreika's "TERMINATED 08/01/2018" entry on CourtListener is inconsistent with a 2015 closure and with the absence of any 2015–2016 withdrawal; I could not source it to a docket entry. Do not rely on it.
4. I did not find or retrieve the original 15-865 complaint's signature block text via search (the complaint text I could open matches the 15-865 patent set — '724, '725, '424, '219, '094 and ANDA No. 206802). If you need the exact filed signature block and any named of-counsel, that requires pulling D.I. 1 / D.I. 7 from PACER for this docket; the RECAP mirror is here.
5. Defendant's counsel (for completeness only, since you asked about plaintiff): Fresenius Kabi was represented in the parallel New Jersey matters by Fox Rothschild LLP (Karen A. Confoy, Lawrenceville, NJ). I did not confirm a Delaware appearance for Fresenius in 15-865 because none was docketed before dismissal. Do not attribute the Fox Rothschild appearance to the 15-865 docket without verification.

I'll research the counsel of record for the defendant in this Delaware ANDA case.

Let me get the actual docket for 1:15-cv-00865 and look for defendant's counsel.

The docket suggests the case was voluntarily dismissed within ~2 months. Let me pull the full docket sheet and any defendant filings.

Counsel of record for the defendant — Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 1:15-cv-00865 (D. Del.)

Bottom line: I could not identify any defense-side attorney of record in this specific case, and the evidence strongly indicates that none ever appeared. This action was filed on Sept. 24, 2015 and dismissed less than ten weeks later, before the defendant was brought into the case.

Why there is no defendant counsel to list

• The RECAP/CourtListener docket for 1:15-cv-00865 lists only plaintiff-side counsel (Morris, Nichols, Arsht & Tunnell: Jack B. Blumenfeld, Karen Jacobs, Maryellen Noreika). The visible docket entries are: complaint (D.I. 1, 9/24/2015); ANDA supplemental-information and Rule 7.1 disclosures; amended complaint (10/14/2015); then a Notice of Voluntary Dismissal of all claims "without prejudice" filed 12/1/2015 (Jacobs, Karen), terminating the case on 12/2/2015, followed by a report to the Commissioner. CourtListener docket 4220916
• The FJC Integrated Database record for this docket confirms the posture: "Procedural Progress: No court action (before issue joined)" and "Disposition: Voluntarily dismissed." That is the FJC code for a case that closed before the defendant appeared/answered — consistent with no defense appearance ever being entered. CourtListener FJC IDB page
• No answer, counterclaim, motion to dismiss, or corporate-disclosure statement on behalf of Fresenius Kabi appears in the retrieved docket.

I am flagging this as a verified absence insofar as the public RECAP record goes, not a claim that PACER contains nothing. RECAP can be incomplete, so the definitive check is the PACER docket sheet for 1:15-cv-00865 itself. If an appearance was filed and never captured by RECAP, it would appear there.

Fresenius Kabi's counsel in the related palonosetron litigations (NOT counsel of record in 1:15-cv-00865)

The D. Del. case was one of a cluster of Helsinn/Roche palonosetron suits filed in the same window. For context — and clearly labeled as not an appearance in this docket — Fresenius Kabi's counsel in the parallel matters were:

• Fox Rothschild LLP — Karen A. Confoy (Partner, Lawrenceville, N.J. office). Ms. Confoy signed the answer for Fresenius Kabi USA, LLC in the parallel D.N.J. action Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 3:15-cv-07378 (D.N.J.) ("FOX ROTHSCHILD LLP … By: Karen A. Confoy … Attorneys for Fresenius Kabi USA, LLC"). Docket Alarm PDF, D.N.J. 3:15-cv-07378, D.I. 11
• Fresenius Kabi was also a defendant in the consolidated D.N.J. actions No. 15-2077, 15-7015, and 15-7378 (consolidated before Judge Mary L. Cooper), where the same patents-in-suit ('724, '725, '424, '219, '094) were at issue. Fox Rothschild is the firm identified as Fresenius's counsel of record in those New Jersey pleadings.

Caution on two red herrings: A separate, earlier D. Del. case (D. Del. No. 1:13-cv-…, RECAP docket ded.49359, dated 9/30/2013) shows Potter Anderson & Corroon LLP (Richard L. Horwitz, David E. Moore, Bindu A. Palapura) appearing for "Fresenius Kabi USA, LLC and Defendants Fresenius Kabi, Inc. and Fresenius Kabi Pharmaceuticals Holding, Inc." That is a different case with different party entities and must not be imported into this docket. Similarly, the well-known Helsinn on-sale-bar litigation Helsinn v. Teva (Sup. Ct. 2019) is a different defendant entirely.

Data-integrity flags against the case metadata

1. Plaintiffs: The supplied metadata lists only "Helsinn Healthcare S.A." as plaintiff. The actual complaint and docket caption name Helsinn Healthcare S.A. and Roche Palo Alto LLC as co-plaintiffs. The metadata appears truncated.
2. Possibly duplicated docket: DrugPatentWatch separately lists Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 1:15-cv-00918 (D. Del.), filed 2015-10-13, also assigned to Judge Sleet and also terminated 2015-12-02, on the same patents. DrugPatentWatch This looks like a companion/duplicate filing tracking a second ANDA notice rather than a distinct merits action, but it should be confirmed and, if real, the two dockets reconciled. The metadata's termination date matches 00865, so the summary is internally consistent.
3. Why it was dismissed: The 12/1/2015 voluntary dismissal "without prejudice," combined with the contemporaneous, actively litigated D.N.J. consolidated actions on the identical patents, suggests Helsinn consolidated its Fresenius Kabi claims in New Jersey rather than pursuing them in Delaware. I have not found a filed explanation of record, so treat that as inference rather than a documented ruling.

Practical next steps for a definitive answer

Because the target case closed pre-answer, the only way to state with certainty whether any defense counsel appeared is to pull the full PACER docket sheet for 1:15-cv-00865 (all entries, including any appearance or pro hac vice motion) and to confirm the 1:15-cv-00918 docket is not the operative one. If the goal is defense counsel "for Fresenius Kabi in the Helsinn palonosetron litigation" generally, the verifiable name is Karen A. Confoy of Fox Rothschild LLP (Lawrenceville, NJ), who appeared for Fresenius Kabi in the parallel D.N.J. actions — not in this Delaware docket.

I have not identified any in-house Fresenius Kabi counsel of record, and I did not find a lead/trial counsel firm for Fresenius in this matter that I can source; I am deliberately not naming one to avoid fabricating an appearance.